Am. J. Respir. Crit. Care Med., Volume 156, Number 2, August 1997, 375-381

Lactoferrin, a Potent Tryptase Inhibitor, Abolishes Late-Phase Airway Responses in Allergic Sheep

KYLE C. ELROD, WILLIAM R. MOORE, WILLIAM M. ABRAHAM, and RICHARD D. TANAKA

Arris Pharmaceutical Corporation, South San Francisco, California; Department of Research, Pulmonary Diseases, University of Miami, Mt. Sinai Medical Center, Miami Beach, Florida

Tryptase, a serine protease released exclusively from activated mast cells, has been implicated as a potential causative agent in asthma. Enzymatically active tryptase is comprised of four subunits, and heparin stabilizes the associated tetramer. Lactoferrin, a cationic protein released from activated neutrophils, binds tightly to heparin, therefore we investigated lactoferrin as an inhibitor of tryptase and found that it is both a potent (K_i' is 24 nM) and selective inhibitor. Size exclusion chromatography studies revealed that lactoferrin disrupted the quaternary structure of active tryptase. Lactoferrin was tested in an allergic sheep model of asthma; aerosolized lactoferrin (10 mg in 3 ml phosphate-buffered saline, 0.5 h before as well as 4 and 24 h after inhalation challenge by Ascaris suum) abolished both late-phase bronchoconstriction (no significant increase in specific lung resistance 4 to 8 h following provocation, p < 0.05 versus vehicle treatment) and airway hyperresponsiveness (no detectable increase in airway sensitivity to carbachol challenge 24 h after antigen challenge, p < 0.05 versus vehicle). These data suggest tryptase involvement in both late-phase bronchoconstriction and airway hyperreactivity and furthermore suggest that a physiological function of neutrophil lactoferrin is the inhibition of tryptase released from mast cells.

This article has been cited by other articles:

				G. W. Krissansen Emerging Health Properties of Whey Proteins and Their Clinical Implications J. Am. Coll. Nutr., December 1, 2007; 26(6): 713S - 723S. [Abstract] [Full Text] [PDF]

				M. B. Frungieri, S. Weidinger, V. Meineke, F. M. Kohn, and A. Mayerhofer Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma : Possible relevance to human fibrotic disorders PNAS, November 12, 2002; 99(23): 15072 - 15077. [Abstract] [Full Text] [PDF]

				S.-W. Oh, C. I. Pae, D.-K. Lee, F. Jones, G. K. S. Chiang, H.-O. Kim, S.-H. Moon, B. Cao, C. Ogbu, K.-W. Jeong, et al. Tryptase Inhibition Blocks Airway Inflammation in a Mouse Asthma Model J. Immunol., February 15, 2002; 168(4): 1992 - 2000. [Abstract] [Full Text] [PDF]

				C. P. SOMMERHOFF Mast Cell Tryptases and Airway Remodeling Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): S52 - 58. [Abstract] [Full Text] [PDF]

				J. Hallgren, D. Spillmann, and G. Pejler Structural Requirements and Mechanism for Heparin-induced Activation of a Recombinant Mouse Mast Cell Tryptase, Mouse Mast Cell Protease-6. FORMATION OF ACTIVE TRYPTASE MONOMERS IN THE PRESENCE OF LOW MOLECULAR WEIGHT HEPARIN J. Biol. Chem., November 9, 2001; 276(46): 42774 - 42781. [Abstract] [Full Text] [PDF]

				P. J. Barnes, K. F. Chung, and C. P. Page Inflammatory Mediators of Asthma: An Update Pharmacol. Rev., December 1, 1998; 50(4): 515 - 596. [Abstract] [Full Text] [PDF]

				A. L. LAMBERT, D. W. WINSETT, D. L. COSTA, M. K. SELGRADE, and M. IAN GILMOUR Transfer of Allergic Airway Responses with Serum and Lymphocytes from Rats Sensitized to Dust Mite Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1991 - 1999. [Abstract] [Full Text] [PDF]